கீழ் சுவாச டிராக் தொற்று News Today : Breaking News, Live Updates & Top Stories | Vimarsana

  and tolerability profile in infants at high risk of RSV     The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season. 1   The trial assessed the safety of nirsevimab in infants with chronic lung disease (CLD), congenital heart disease (CHD) and/or prematurity. Occurrence of treatment emergent adverse events (TEAEs) or treatment emergent serious adverse events (TESAEs) were similar between groups. 1   Nirsevimab is a long-acting antibody, using AstraZeneca s proprietary YTE technology, being developed by AstraZeneca and Sanofi with the potential

New yorkUnited statesUnited kingdomSanofi pasteurJoseph domachowskeAstrazeneca synagisAdrian kempHospitalizations among children aged lancet glob healthCenters for diseaseDrug administrationEuropean medicines agency priorityCompany on twitter astrazenecaGlobal head of researchUniversity of new yorkInvestor relations teamNational medical products administration